Emergent BioSolutions Inc. (NYSE: EBS) Stock Competitors & Peer Comparison
See EBS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EBS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EBS | $5.08 | +5.39% | 262.4M | 3.53 | $1.44 | N/A |
| TAK | $18.18 | +0.28% | 57.9B | 13.07 | $1.39 | +3.47% |
| HLN | $10.00 | +1.32% | 44.1B | 18.66 | $0.54 | +1.24% |
| TEVA | $37.34 | +1.44% | 43.5B | 12.74 | $2.93 | N/A |
| ZTS | $77.73 | +3.61% | 32.6B | 11.81 | $6.58 | +2.69% |
| VTRS | $16.32 | +1.24% | 19B | 6.48 | $2.52 | +2.94% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.97 | +1.74% | 12B | 22.62 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.18 | +0.58% | 10.2B | 19.98 | $0.61 | +0.68% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
EBS vs TAK Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TAK has a market cap of 57.9B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TAK trades at $18.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TAK's P/E ratio is 13.07. In terms of profitability, EBS's ROE is -0.36%, compared to TAK's ROE of +0.02%. Regarding short-term risk, EBS is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TAK's competition here
Haleon plc (NYSE: HLN)
EBS vs HLN Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, HLN has a market cap of 44.1B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while HLN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas HLN's P/E ratio is 18.66. In terms of profitability, EBS's ROE is -0.36%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EBS is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
EBS vs TEVA Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TEVA has a market cap of 43.5B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TEVA trades at $37.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TEVA's P/E ratio is 12.74. In terms of profitability, EBS's ROE is -0.36%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, EBS is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
EBS vs ZTS Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ZTS has a market cap of 32.6B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ZTS trades at $77.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ZTS's P/E ratio is 11.81. In terms of profitability, EBS's ROE is -0.36%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, EBS is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
EBS vs VTRS Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while VTRS trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas VTRS's P/E ratio is 6.48. In terms of profitability, EBS's ROE is -0.36%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, EBS is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
EBS vs ITCI Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EBS's ROE is -0.36%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EBS is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
EBS vs ELAN Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ELAN has a market cap of 12B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ELAN trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ELAN's P/E ratio is 22.62. In terms of profitability, EBS's ROE is -0.36%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, EBS is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
EBS vs CTLT Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EBS's ROE is -0.36%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EBS is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
EBS vs RDY Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while RDY trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas RDY's P/E ratio is 19.98. In terms of profitability, EBS's ROE is -0.36%, compared to RDY's ROE of +0.09%. Regarding short-term risk, EBS is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for EBS.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
EBS vs LNTH Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while LNTH trades at $99.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas LNTH's P/E ratio is 16.80. In terms of profitability, EBS's ROE is -0.36%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, EBS is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
EBS vs AMRX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while AMRX trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas AMRX's P/E ratio is 19.90. In terms of profitability, EBS's ROE is -0.36%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, EBS is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
EBS vs INDV Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while INDV trades at $36.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas INDV's P/E ratio is 10.10. In terms of profitability, EBS's ROE is -0.36%, compared to INDV's ROE of -2.16%. Regarding short-term risk, EBS is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for EBS.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
EBS vs SUPN Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while SUPN trades at $45.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas SUPN's P/E ratio is 14.98. In terms of profitability, EBS's ROE is -0.36%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, EBS is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
EBS vs RGC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, RGC has a market cap of 2.6B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while RGC trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas RGC's P/E ratio is -373.24. In terms of profitability, EBS's ROE is -0.36%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EBS is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
EBS vs BHC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while BHC trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas BHC's P/E ratio is 1.64. In terms of profitability, EBS's ROE is -0.36%, compared to BHC's ROE of +0.89%. Regarding short-term risk, EBS is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
EBS vs DCPH Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EBS's ROE is -0.36%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EBS is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
EBS vs HCM Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while HCM trades at $12.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas HCM's P/E ratio is 4.73. In terms of profitability, EBS's ROE is -0.36%, compared to HCM's ROE of +0.01%. Regarding short-term risk, EBS is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
EBS vs AVDL Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EBS's ROE is -0.36%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, EBS is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AVDL's competition here
Alvotech (NASDAQ: ALVOW)
EBS vs ALVOW Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ALVOW has a market cap of 2B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ALVOW trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ALVOW's P/E ratio is 32.08. In terms of profitability, EBS's ROE is -0.36%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, EBS is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALVOW's competition here
Perrigo Company plc (NYSE: PRGO)
EBS vs PRGO Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while PRGO trades at $14.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas PRGO's P/E ratio is 5.70. In terms of profitability, EBS's ROE is -0.36%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, EBS is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
EBS vs EMBCV Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas EMBCV's P/E ratio is N/A. In terms of profitability, EBS's ROE is -0.36%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, EBS is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for EBS.Check EMBCV's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
EBS vs TRLV Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TRLV trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TRLV's P/E ratio is -4.51. In terms of profitability, EBS's ROE is -0.36%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, EBS is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TRLV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
EBS vs DVAX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EBS's ROE is -0.36%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, EBS is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DVAX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
EBS vs ETON Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ETON has a market cap of 1.7B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ETON trades at $63.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ETON's P/E ratio is -906.71. In terms of profitability, EBS's ROE is -0.36%, compared to ETON's ROE of +0.40%. Regarding short-term risk, EBS is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
EBS vs ANIP Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ANIP trades at $75.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ANIP's P/E ratio is 9.17. In terms of profitability, EBS's ROE is -0.36%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, EBS is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
EBS vs TARO Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TARO's P/E ratio is 30.05. In terms of profitability, EBS's ROE is -0.36%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EBS is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
EBS vs HROW Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while HROW trades at $40.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas HROW's P/E ratio is -41.36. In terms of profitability, EBS's ROE is -0.36%, compared to HROW's ROE of -1.04%. Regarding short-term risk, EBS is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for EBS.Check HROW's competition here
Alvotech (NASDAQ: ALVO)
EBS vs ALVO Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ALVO has a market cap of 1.5B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ALVO trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ALVO's P/E ratio is -13.03. In terms of profitability, EBS's ROE is -0.36%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, EBS is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALVO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
EBS vs PAHC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while PAHC trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas PAHC's P/E ratio is 12.40. In terms of profitability, EBS's ROE is -0.36%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EBS is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
EBS vs CRON Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while CRON trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas CRON's P/E ratio is 30.58. In terms of profitability, EBS's ROE is -0.36%, compared to CRON's ROE of +0.06%. Regarding short-term risk, EBS is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
EBS vs PCRX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, PCRX has a market cap of 970.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while PCRX trades at $24.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas PCRX's P/E ratio is 9.49. In terms of profitability, EBS's ROE is -0.36%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, EBS is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PCRX's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
EBS vs AMPH Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, AMPH has a market cap of 952.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while AMPH trades at $21.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas AMPH's P/E ratio is 7.37. In terms of profitability, EBS's ROE is -0.36%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EBS is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
EBS vs PETQ Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EBS's ROE is -0.36%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EBS is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
EBS vs COLL Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, COLL has a market cap of 893.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while COLL trades at $27.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas COLL's P/E ratio is 3.46. In terms of profitability, EBS's ROE is -0.36%, compared to COLL's ROE of +0.16%. Regarding short-term risk, EBS is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
EBS vs IRWD Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, IRWD has a market cap of 706.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while IRWD trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas IRWD's P/E ratio is 5.50. In terms of profitability, EBS's ROE is -0.36%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, EBS is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for EBS.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
EBS vs EVO Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, EVO has a market cap of 685.6M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while EVO trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas EVO's P/E ratio is -2.73. In terms of profitability, EBS's ROE is -0.36%, compared to EVO's ROE of -0.27%. Regarding short-term risk, EBS is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
EBS vs AQST Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, AQST has a market cap of 584.7M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while AQST trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas AQST's P/E ratio is -7.64. In terms of profitability, EBS's ROE is -0.36%, compared to AQST's ROE of +2.44%. Regarding short-term risk, EBS is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
EBS vs BDSI Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EBS's ROE is -0.36%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EBS is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
EBS vs EOLS Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, EOLS has a market cap of 552.5M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while EOLS trades at $8.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas EOLS's P/E ratio is -26.57. In terms of profitability, EBS's ROE is -0.36%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, EBS is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EOLS's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
EBS vs TLRY Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TLRY has a market cap of 541.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TLRY trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TLRY's P/E ratio is -4.46. In terms of profitability, EBS's ROE is -0.36%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, EBS is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
EBS vs KMDA Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, KMDA has a market cap of 475.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while KMDA trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas KMDA's P/E ratio is 21.68. In terms of profitability, EBS's ROE is -0.36%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EBS is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
EBS vs CGC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, CGC has a market cap of 443.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while CGC trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas CGC's P/E ratio is -0.63. In terms of profitability, EBS's ROE is -0.36%, compared to CGC's ROE of -0.33%. Regarding short-term risk, EBS is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
EBS vs TKNO Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TKNO has a market cap of 394.6M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TKNO trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TKNO's P/E ratio is -23.74. In terms of profitability, EBS's ROE is -0.36%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, EBS is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for EBS.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
EBS vs ALIM Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EBS's ROE is -0.36%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EBS is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
EBS vs LNDC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EBS's ROE is -0.36%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, EBS is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
EBS vs ACB Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ACB has a market cap of 244.1M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ACB trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ACB's P/E ratio is -8.04. In terms of profitability, EBS's ROE is -0.36%, compared to ACB's ROE of -0.21%. Regarding short-term risk, EBS is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
EBS vs ORGO Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ORGO has a market cap of 231.6M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ORGO trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ORGO's P/E ratio is 60.00. In terms of profitability, EBS's ROE is -0.36%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, EBS is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
EBS vs TYHT Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EBS's ROE is -0.36%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, EBS is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
EBS vs SIGA Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, SIGA has a market cap of 218M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while SIGA trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas SIGA's P/E ratio is 11.26. In terms of profitability, EBS's ROE is -0.36%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, EBS is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SIGA's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
EBS vs CRDL Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, CRDL has a market cap of 217.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while CRDL trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas CRDL's P/E ratio is -7.51. In terms of profitability, EBS's ROE is -0.36%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, EBS is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CRDL's competition here
Journey Medical Corporation (NASDAQ: DERM)
EBS vs DERM Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, DERM has a market cap of 213.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while DERM trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas DERM's P/E ratio is -20.95. In terms of profitability, EBS's ROE is -0.36%, compared to DERM's ROE of -0.20%. Regarding short-term risk, EBS is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
EBS vs REPH Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas REPH's P/E ratio is -8.04. In terms of profitability, EBS's ROE is -0.36%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EBS is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
EBS vs OGI Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, OGI has a market cap of 176M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas OGI's P/E ratio is -4.81. In terms of profitability, EBS's ROE is -0.36%, compared to OGI's ROE of +0.21%. Regarding short-term risk, EBS is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
EBS vs LFCR Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, LFCR has a market cap of 170.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while LFCR trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas LFCR's P/E ratio is -4.24. In terms of profitability, EBS's ROE is -0.36%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, EBS is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for EBS.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
EBS vs THTX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas THTX's P/E ratio is -28.83. In terms of profitability, EBS's ROE is -0.36%, compared to THTX's ROE of +0.17%. Regarding short-term risk, EBS is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
EBS vs ASRT Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ASRT's P/E ratio is -7.10. In terms of profitability, EBS's ROE is -0.36%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EBS is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
EBS vs SCTL Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EBS's ROE is -0.36%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EBS is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
EBS vs CPIX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, CPIX has a market cap of 112.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while CPIX trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas CPIX's P/E ratio is -18.75. In terms of profitability, EBS's ROE is -0.36%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, EBS is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
EBS vs PROC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas PROC's P/E ratio is 1.53. In terms of profitability, EBS's ROE is -0.36%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EBS is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PROC's competition here
BGM Group Ltd. (NASDAQ: BGM)
EBS vs BGM Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, BGM has a market cap of 101.1M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while BGM trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas BGM's P/E ratio is -0.92. In terms of profitability, EBS's ROE is -0.36%, compared to BGM's ROE of -0.07%. Regarding short-term risk, EBS is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check BGM's competition here
OptiNose, Inc. (NASDAQ: OPTN)
EBS vs OPTN Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EBS's ROE is -0.36%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, EBS is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for EBS.Check OPTN's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
EBS vs ZYBT Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ZYBT has a market cap of 96.7M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ZYBT trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ZYBT's P/E ratio is -9.27. In terms of profitability, EBS's ROE is -0.36%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, EBS is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ZYBT's competition here
Zomedica Corp. (AMEX: ZOM)
EBS vs ZOM Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EBS's ROE is -0.36%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, EBS is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
EBS vs GRVI Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EBS's ROE is -0.36%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, EBS is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
EBS vs ZYNE Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EBS's ROE is -0.36%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EBS is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
EBS vs SSIC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EBS's ROE is -0.36%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EBS is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
EBS vs TLPH Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TLPH trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TLPH's P/E ratio is -3.84. In terms of profitability, EBS's ROE is -0.36%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, EBS is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
EBS vs VLNS Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EBS's ROE is -0.36%, compared to VLNS's ROE of N/A. Regarding short-term risk, EBS is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for EBS.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
EBS vs DRRX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EBS's ROE is -0.36%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, EBS is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
EBS vs INCR Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, INCR has a market cap of 51.5M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while INCR trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas INCR's P/E ratio is -2.01. In terms of profitability, EBS's ROE is -0.36%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EBS is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for EBS.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
EBS vs JUPW Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EBS's ROE is -0.36%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, EBS is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for EBS.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
EBS vs CPHI Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, CPHI has a market cap of 42.5M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while CPHI trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas CPHI's P/E ratio is -1.64. In terms of profitability, EBS's ROE is -0.36%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, EBS is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
EBS vs QLI Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas QLI's P/E ratio is -4.92. In terms of profitability, EBS's ROE is -0.36%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EBS is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
EBS vs RMTI Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, RMTI has a market cap of 32M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while RMTI trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas RMTI's P/E ratio is -6.04. In terms of profitability, EBS's ROE is -0.36%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, EBS is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for EBS.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
EBS vs HEXO Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EBS's ROE is -0.36%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EBS is similarly volatile compared to HEXO. This indicates similar risk in terms of short-term price fluctuations for EBS.Check HEXO's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
EBS vs AYTU Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, AYTU has a market cap of 25.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while AYTU trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas AYTU's P/E ratio is -1.23. In terms of profitability, EBS's ROE is -0.36%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, EBS is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for EBS.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
EBS vs TXMD Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, TXMD has a market cap of 23.8M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while TXMD trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas TXMD's P/E ratio is 104.94. In terms of profitability, EBS's ROE is -0.36%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, EBS is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for EBS.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
EBS vs CYTH Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EBS's ROE is -0.36%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EBS is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
EBS vs EVOK Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EBS's ROE is -0.36%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, EBS is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for EBS.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
EBS vs OPTH Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, OPTH has a market cap of 16.1M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while OPTH trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas OPTH's P/E ratio is -18.30. In terms of profitability, EBS's ROE is -0.36%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, EBS is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
EBS vs ACRX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EBS's ROE is -0.36%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, EBS is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for EBS.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
EBS vs CABR Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, CABR has a market cap of 12.1M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while CABR trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas CABR's P/E ratio is -2.37. In terms of profitability, EBS's ROE is -0.36%, compared to CABR's ROE of -3.28%. Regarding short-term risk, EBS is more volatile compared to CABR. This indicates higher risk in terms of short-term price fluctuations for EBS.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
EBS vs AGRX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EBS's ROE is -0.36%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EBS is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
EBS vs NLTX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EBS's ROE is -0.36%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, EBS is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
EBS vs LCI Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas LCI's P/E ratio is -0.04. In terms of profitability, EBS's ROE is -0.36%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EBS is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for EBS.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
EBS vs ADMP Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EBS's ROE is -0.36%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EBS is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
EBS vs YCBD Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, YCBD has a market cap of 5.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while YCBD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas YCBD's P/E ratio is -1.25. In terms of profitability, EBS's ROE is -0.36%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EBS is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for EBS.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
EBS vs GELS Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, GELS has a market cap of 4.9M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas GELS's P/E ratio is -1.07. In terms of profitability, EBS's ROE is -0.36%, compared to GELS's ROE of -0.25%. Regarding short-term risk, EBS is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for EBS.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
EBS vs MNK Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas MNK's P/E ratio is -0.44. In terms of profitability, EBS's ROE is -0.36%, compared to MNK's ROE of -0.36%. Regarding short-term risk, EBS is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for EBS.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
EBS vs FLGC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EBS's ROE is -0.36%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, EBS is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
EBS vs UPC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, UPC has a market cap of 3.4M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while UPC trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas UPC's P/E ratio is -0.68. In terms of profitability, EBS's ROE is -0.36%, compared to UPC's ROE of -0.03%. Regarding short-term risk, EBS is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for EBS.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
EBS vs SBFM Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, SBFM has a market cap of 2.8M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while SBFM trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas SBFM's P/E ratio is -0.19. In terms of profitability, EBS's ROE is -0.36%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, EBS is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
EBS vs PLXP Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EBS's ROE is -0.36%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EBS is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for EBS.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
EBS vs ATNX Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EBS's ROE is -0.36%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EBS is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for EBS.Check ATNX's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
EBS vs SHPH Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, SHPH has a market cap of 2.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while SHPH trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas SHPH's P/E ratio is -0.18. In terms of profitability, EBS's ROE is -0.36%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, EBS is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SHPH's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
EBS vs SNOA Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas SNOA's P/E ratio is -1.14. In terms of profitability, EBS's ROE is -0.36%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, EBS is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for EBS.Check SNOA's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
EBS vs SXTC Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, SXTC has a market cap of 2.2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while SXTC trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas SXTC's P/E ratio is 1.47. In terms of profitability, EBS's ROE is -0.36%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, EBS is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for EBS.Check SXTC's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
EBS vs RDHL Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, RDHL has a market cap of 2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas RDHL's P/E ratio is 0.13. In terms of profitability, EBS's ROE is -0.36%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, EBS is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for EBS.Check RDHL's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
EBS vs PROCW Comparison August 2026
Emergent BioSolutions Inc. (NYSE: EBS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EBS stands at 262.4M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, EBS is priced at $5.08 on the NYSE, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EBS currently has a P/E ratio of 3.53, whereas PROCW's P/E ratio is N/A. In terms of profitability, EBS's ROE is -0.36%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, EBS is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for EBS.Check PROCW's competition here